Bösze Zsuzsanna, Baranyi Mária, Whitelaw C Bruce A
Agricultural Biotechnology Center, Gödöllõ, Hungary.
Adv Exp Med Biol. 2008;606:357-93. doi: 10.1007/978-0-387-74087-4_15.
Recombinant human proteins produced by the mammary glands of genetically modified transgenic livestock mammals represent a special aspect of milk bioactive components. For therapeutic applications, the often complex posttranslational modifications of human proteins should be recapitulated in the recombinant products. Compared to alternative production methods, mammary gland production is a viable option, underlined by a number of transgenic livestock animal models producing abundant biologically active foreign proteins in their milk. Recombinant proteins isolated from milk have reached different phases of clinical trials, with the first marketing approval for human therapeutic applications from the EMEA achieved in 2006.
转基因家畜哺乳动物乳腺产生的重组人蛋白是乳汁生物活性成分的一个特殊方面。对于治疗应用而言,重组产品应重现人蛋白通常复杂的翻译后修饰。与其他生产方法相比,乳腺生产是一种可行的选择,许多转基因家畜动物模型在其乳汁中产生大量具有生物活性的外源蛋白就证明了这一点。从乳汁中分离的重组蛋白已进入不同阶段的临床试验,2006年欧洲药品管理局首次批准其用于人类治疗应用。